Delcath Systems, Inc. (DCTH)

USD 10.21

(-7.31%)

Market Cap (In USD)

341.17 Million

Revenue (In USD)

2.06 Million

Net Income (In USD)

-47.67 Million

Avg. Volume

475.92 Thousand

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
3.43-13.301
PE
-10.97
EPS
-0.93
Beta Value
0.76
ISIN
US24661P8077
CUSIP
24661P807
CIK
872912
Shares
33432600.0
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Medical - Specialties
CEO
Mr. Gerard J. Michel MBA, MS
Employee Count
-
Website
https://www.delcath.com
Ipo Date
2018-05-03
Details
Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal Melanoma to investigate objective response rate in metastatic uveal melanoma. It also provides HEPZATO as a stand-alone medical device under the CHEMOSAT Hepatic Delivery System trade name for Melphalan or CHEMOSAT for medical centers to treat a range of liver cancers in Europe. Delcath Systems, Inc. was incorporated in 1988 and is headquartered in New York, New York.